- Home
- XPON vs SILO Comparison
XPON vs SILO Comparison
Compare XPON & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPON
- SILO
- Stock Information
- Founded
- XPON 2016
- SILO 2010
- Country
- XPON United States
- SILO United States
- Employees
- XPON N/A
- SILO N/A
- Industry
- XPON Electronic Components
- SILO Apparel
- Sector
- XPON Technology
- SILO Consumer Discretionary
- Exchange
- XPON Nasdaq
- SILO Nasdaq
- Market Cap
- XPON 3.1M
- SILO 3.1M
- IPO Year
- XPON 2022
- SILO N/A
- Fundamental
- Price
- XPON $0.96
- SILO $0.58
- Analyst Decision
- XPON
- SILO
- Analyst Count
- XPON 0
- SILO 0
- Target Price
- XPON N/A
- SILO N/A
- AVG Volume (30 Days)
- XPON 339.1K
- SILO 2.4M
- Earning Date
- XPON 05-15-2025
- SILO 05-09-2025
- Dividend Yield
- XPON N/A
- SILO N/A
- EPS Growth
- XPON N/A
- SILO N/A
- EPS
- XPON N/A
- SILO N/A
- Revenue
- XPON $6,702,411.00
- SILO $72,102.00
- Revenue This Year
- XPON $61.26
- SILO $1.86
- Revenue Next Year
- XPON N/A
- SILO N/A
- P/E Ratio
- XPON N/A
- SILO N/A
- Revenue Growth
- XPON 23.07
- SILO N/A
- 52 Week Low
- XPON $0.60
- SILO $0.41
- 52 Week High
- XPON $164.00
- SILO $4.50
- Technical
- Relative Strength Index (RSI)
- XPON 55.04
- SILO 45.16
- Support Level
- XPON $0.88
- SILO $0.43
- Resistance Level
- XPON $0.97
- SILO $0.49
- Average True Range (ATR)
- XPON 0.11
- SILO 0.06
- MACD
- XPON 0.01
- SILO 0.03
- Stochastic Oscillator
- XPON 90.00
- SILO 45.03
About XPON Expion360 Inc.
Expion360 Inc is focused on the design, assembly, manufacturing, and sales of lithium iron phosphate (LiFePO4) batteries and supporting accessories for recreational vehicles (RV's) and marine applications with plans to expand into home energy storage products and industrial applications. Its product offerings include some of the minimal-footprint batteries in the RV & Marine industry.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.